Bacterial Mucosal Vaccines: Vibrio cholerae as a Live Attenuated Vaccine/Vector Paradigm

Author(s):  
K. Killeen ◽  
D. Spriggs ◽  
J. Mekalanos
2000 ◽  
Vol 68 (1) ◽  
pp. 221-226 ◽  
Author(s):  
Edward T. Ryan ◽  
Thomas I. Crean ◽  
Sims K. Kochi ◽  
Manohar John ◽  
Angel A. Luciano ◽  
...  

ABSTRACT We have previously shown that more prominent immune responses are induced to antigens expressed from multicopy plasmids in live attenuated vaccine vector strains of Vibrio cholerae than to antigens expressed from single-copy genes on the V. cholerae chromosome. Here, we report the construction of a ΔglnA derivative of V. cholerae vaccine strain Peru2. This mutant strain, Peru2ΔglnA, is unable to grow on medium that does not contain glutamine; this growth deficiency is complemented by pKEK71-NotI, a plasmid containing a complete copy of the Salmonella typhimurium glnA gene, or by pTIC5, a derivative of pKEK71-NotI containing a 1.8-kbp fragment that directs expression of CtxB with a 12-amino-acid epitope of the serine-rich Entamoeba histolytica protein fused to the amino terminus. Strain Peru2ΔglnA(pTIC5) produced 10-fold more SREHP-12-CtxB in supernatants than did ETR3, a Peru2-derivative strain containing the same fragment inserted on the chromosome. To assess immune responses to antigens expressed by this balanced lethal system in vivo, we inoculated germfree mice on days 0, 14, 28, and 42 with Peru2ΔglnA, Peru2ΔglnA(pKEK71-NotI), Peru2(pTIC5), Peru2ΔglnA(pTIC5), or ETR3. All V. cholerae strains were recoverable from stool for 8 to 12 days after primary inoculation, including Peru2ΔglnA; strains containing plasmids continued to harbor pKEK71-NotI or pTIC5 for 8 to 10 days after primary inoculation. Animals were sacrificed on day 56, and serum, stool and biliary samples were analyzed for immune responses. Vibriocidal antibody responses, reflective of in vivo colonization, were equivalent in all groups of animals. However, specific anti-CtxB immune responses in serum (P ≤ 0.05) and bile (P ≤ 0.001) were significantly higher in animals that received Peru2ΔglnA(pTIC5) than in those that received ETR3, confirming the advantage of higher-level antigen expression in vivo. The development of this balanced lethal system thus permits construction and maintenance of vaccine and vector strains of V. cholerae that express high levels of immunogenic antigens from plasmid vectors without the need for antibiotic selection pressure.


2020 ◽  
Vol 94 (19) ◽  
Author(s):  
Chengjin Ye ◽  
Juan Carlos de la Torre ◽  
Luis Martínez-Sobrido

ABSTRACT The New World mammarenavirus Tacaribe virus (TCRV) has been isolated from fruit bats, mosquitoes, and ticks, whereas all other known New World mammarenaviruses are maintained in rodents. TCRV has not been linked to human disease, but it has been shown to protect against Argentine hemorrhagic fever-like disease in marmosets infected with the New World mammarenavirus Junín virus (JUNV), indicating the potential of TCRV as a live-attenuated vaccine for the treatment of Argentine hemorrhagic fever. Implementation of TCRV as a live-attenuated vaccine or a vaccine vector would be facilitated by the establishment of reverse genetics systems for the genetic manipulation of the TCRV genome. In this study, we developed, for the first time, reverse genetics approaches for the generation of recombinant TCRV (rTCRV). We successfully rescued a wild-type (WT) rTCRV (a trisegmented form of TCRV expressing two reporter genes [r3TCRV]) and a bisegmented TCRV expressing a single reporter gene from a bicistronic viral mRNA (rTCRV/GFP). These reverse genetics approaches represent an excellent tool to investigate the biology of TCRV and to explore its potential use as a live-attenuated vaccine or a vaccine vector for the treatment of other viral infections. Notably, we identified a 39-nucleotide (nt) deletion (Δ39) in the noncoding intergenic region (IGR) of the viral large (L) segment that is required for optimal virus multiplication. Accordingly, an rTCRV containing this 39-nt deletion in the L-IGR (rTCRV/Δ39) exhibited decreased viral fitness in cultured cells, suggesting the feasibility of using this deletion in the L-IGR as an approach to attenuate TCRV, and potentially other mammarenaviruses, for their implementation as live-attenuated vaccines or vaccine vectors. IMPORTANCE To date, no Food and Drug Administration (FDA)-approved vaccines are available to combat hemorrhagic fever caused by mammarenavirus infections in humans. Treatment of mammarenavirus infections is limited to the off-label use of ribavirin, which is partially effective and associated with significant side effects. Tacaribe virus (TCRV), the prototype member of the New World mammarenaviruses, is nonpathogenic in humans but able to provide protection against Junín virus (JUNV), the causative agent of Argentine hemorrhagic fever, demonstrating the feasibility of using TCRV as a live-attenuated vaccine vector for the treatment of JUNV and potentially other viral infections. Here, we describe for the first time the feasibility of generating recombinant TCRV (rTCRV) using reverse genetics approaches, which paves the way to study the biology of TCRV and also its potential use as a live-attenuated vaccine or a vaccine vector for the treatment of mammarenavirus and/or other viral infections in humans.


iScience ◽  
2021 ◽  
pp. 102941
Author(s):  
Jun-Guy Park ◽  
Fatai S. Oladunni ◽  
Mohammed A. Rohaim ◽  
Jayde Whittingham-Dowd ◽  
James Tollitt ◽  
...  

Vaccines ◽  
2018 ◽  
Vol 6 (3) ◽  
pp. 47 ◽  
Author(s):  
Raffael Nachbagauer ◽  
Florian Krammer ◽  
Randy Albrecht

Influenza viruses cause severe diseases and mortality in humans on an annual basis. The current influenza virus vaccines can confer protection when they are well-matched with the circulating strains. However, due to constant changes of the virus surface glycoproteins, the vaccine efficacy can drop substantially in some seasons. In addition, the current seasonal influenza virus vaccines do not protect from avian influenza viruses of human pandemic potential. Novel influenza virus vaccines that aim to elicit antibodies against conserved epitopes like the hemagglutinin stalk could not only reduce the burden of drifted seasonal viruses but potentially also protect humans from infection with zoonotic and emerging pandemic influenza viruses. In this paper, we generated influenza virus vaccine constructs that express chimeric hemagglutinins consisting of exotic, avian head domains and a consistent stalk domain of a seasonal virus. Using such viruses in a sequential immunization regimen can redirect the immune response towards conserved epitopes. In this study, male ferrets received a live-attenuated vaccine virus based on the A/Ann Arbor/6/60 strain expressing a chimeric H8/1 (cH8/1) hemagglutinin, which was followed by a heterologous booster vaccination with a cH5/1N1 formalin inactivated non-adjuvanted whole virus. This group was compared to a second group that received a cH8/1N1 inactivated vaccine followed by a cH5/1N1 inactivated vaccine. Both groups showed a reduction in viral titers in the upper respiratory tract after the A(H1N1)pdm09 virus challenge. Animals that received the live-attenuated vaccine had low or undetectable titers in the lower respiratory tract. The results support the further development of chimeric hemagglutinin-based vaccination strategies. The outcome of this study confirms and corroborates findings from female ferrets primed with a A/Leningrad/134/17/57-based live attenuated cH8/1N1 vaccine followed by vaccination with an AS03-adjuvanted cH5/1N1 split virus vaccine 10.


1982 ◽  
Vol 2 (6) ◽  
pp. 355-360 ◽  
Author(s):  
Osamu Sasaki ◽  
Yoshiaki Karoji ◽  
Akio Kuroda ◽  
Toshiro Karaki ◽  
Kunihachi Takenokuma ◽  
...  

Vaccine ◽  
2021 ◽  
Vol 39 (39) ◽  
pp. 5680-5687
Author(s):  
Yoshihiko Morikawa ◽  
Hiroshi Sakakibara ◽  
Takahisa Kimiya ◽  
Toshimasa Obonai ◽  
Masaru Miura

2009 ◽  
Vol 200 (2) ◽  
pp. 263-272 ◽  
Author(s):  
Benjamin K. Billips ◽  
Ryan E. Yaggie ◽  
John P. Cashy ◽  
Anthony J. Schaeffer ◽  
David J. Klumpp

Vaccine ◽  
2018 ◽  
Vol 36 (52) ◽  
pp. 8001-8007 ◽  
Author(s):  
Shilong Chen ◽  
Fengqiang Lin ◽  
Shaoying Chen ◽  
Qilin Hu ◽  
Xiaoxia Cheng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document